A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)



Status:Recruiting
Conditions:Skin and Soft Tissue Infections, Skin and Soft Tissue Infections
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:7 - Any
Updated:8/30/2018
Start Date:July 1, 2016
End Date:December 2033
Contact:Peter Marinkovich, M.D
Email:mpm@stanford.edu
Phone:650-723-6316

Use our guide to learn which trials are right for you!

A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

The purpose of this study is to evaluate the safety of FCX-007, evaluate C7 expression and
the presence of anchoring fibrils resulting from FCX-007 and to analyze wound healing as a
result of FCX-007 administration in subjects with RDEB.

RDEB is a congenital and progressive orphan skin disease caused by the deficiency of the
protein type VII collagen (COL7). The objective of this study is evaluate the safety FCX-007
intradermal injections in RDEB subjects. Additionally, the trial will evaluate type VII
collagen expression, the presence of anchoring fibrils resulting from FCX-007, as well
evidence of wound healing.

Six adult subjects are expected to be treated with FCX-007 in the Phase I portion of the
trial and six subjects age 7 or older in the Phase II portion of the trial. All subjects will
receive FCX-007 to one or more paired target RDEB wounds. Proof of mechanism will be
monitored through digital photography of target wounds and assays conducted on biopsies taken
from target wounds.

Inclusion Criteria:

1. Age

1. Phase I (subjects 1 through 6): Eighteen (18) years or older.

2. Phase II (subjects 7 through 12): Seven (7) years or older.

2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)

3. NC1/NC2 Status (to be tested for if unknown)

4. Subjects, who are, in the opinion of the Investigator, able to understand the study,
co-operate with the study procedures and are willing to return to the clinic for all
the required follow-up visits

Exclusion Criteria:

1. Medical instability limiting ability to travel to the investigative center.

2. Active infection with HIV, hepatitis B or hepatitis C

3. A positive study specific immunofluorescence result

4. Evidence of systemic infection

5. Current evidence of metastatic squamous cell carcinoma at the site to be injected

6. Known allergy to any of the constituents of the product

7. Active drug or alcohol addiction

8. Hypersensitivity to type of anesthesia chosen

9. Receipt of a chemical or biological study product for the specific treatment of RDEB
in the past six months

10. Women who are pregnant or breast-feeding

11. Abnormal clinically significant laboratory result

12. Clinically significant abnormalities on NCI toxicity scale
We found this trial at
2
sites
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Peter Marinkovich, M.D.
Phone: 408-348-0614
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Anna Bruckner, M.D.
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials